These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21116799)

  • 1. HIV drug resistance testing.
    Cane P
    Methods Mol Biol; 2011; 665():123-32. PubMed ID: 21116799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects.
    Vicenti I; Razzolini F; Saladini F; Romano L; Zazzi M
    Clin Infect Dis; 2007 Jun; 44(12):1657-61. PubMed ID: 17516412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV resistance testing. A clinical tool.
    Paul SM; Jorden VS
    N J Med; 2003 Sep; 100(9 Suppl):44-9; quiz 75-6. PubMed ID: 14556603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2008 May; 46(10):1630-1. PubMed ID: 18419506
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Waters et al. "Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia ...".
    Kan VL; Gale HB; Shinol RC
    AIDS; 2006 Oct; 20(15):1991-2. PubMed ID: 16988529
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml.
    Waters L; Mandalia S; Asboe D
    AIDS; 2006 Mar; 20(5):778-9. PubMed ID: 16514311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.
    Hoffmann C; Minkah N; Leipzig J; Wang G; Arens MQ; Tebas P; Bushman FD
    Nucleic Acids Res; 2007; 35(13):e91. PubMed ID: 17576693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance and replication capacity assays: clinical utility and interpretation.
    Haubrich RH
    Top HIV Med; 2004; 12(2):52-6. PubMed ID: 15184711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in São Paulo, Brazil.
    Rodrigues R; Custódio RM; Bueno SM; Eira M; Ferreira JL; Jamal L; Duarte AJ; Brígido LF
    J Clin Virol; 2005 Apr; 32(4):336-7. PubMed ID: 15780815
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.
    DiRienzo AG; DeGruttola V; Larder B; Hertogs K
    Stat Med; 2003 Sep; 22(17):2785-98. PubMed ID: 12939786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
    Wirden M; Soulie C; Valantin MA; Fourati S; Simon A; Lambert-Niclot S; Bonmarchand M; Clavel-Osorio C; Marcelin AG; Katlama C; Calvez V
    J Antimicrob Chemother; 2011 Apr; 66(4):709-12. PubMed ID: 21393164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIV resistance testing. Introduction of a new technique].
    Dragsted UB; Benfield TL
    Ugeskr Laeger; 2002 Apr; 164(17):2263-7. PubMed ID: 11989174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.